Neuromeka Statistics

Total Valuation

Neuromeka has a market cap or net worth of KRW 294.21 billion. The enterprise value is 329.77 billion.

Market Cap	294.21B
Enterprise Value	329.77B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Neuromeka has 11.34 million shares outstanding. The number of shares has increased by 1.18% in one year.

Current Share Class	11.34M
Shares Outstanding	11.34M
Shares Change (YoY)	+1.18%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	20.29%
Owned by Institutions (%)	2.03%
Float	8.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.64
PB Ratio	27.07
P/TBV Ratio	27.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-19.68
EV / Sales	13.05
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.26

Financial Position

The company has a current ratio of 0.73, with a Debt / Equity ratio of 5.11.

Current Ratio	0.73
Quick Ratio	0.47
Debt / Equity	5.11
Debt / EBITDA	n/a
Debt / FCF	-1.56
Interest Coverage	-3.94

Financial Efficiency

Return on equity (ROE) is -95.95% and return on invested capital (ROIC) is -18.46%.

Return on Equity (ROE)	-95.95%
Return on Assets (ROA)	-12.73%
Return on Invested Capital (ROIC)	-18.46%
Return on Capital Employed (ROCE)	-52.55%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.26
Inventory Turnover	3.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.00% in the last 52 weeks. The beta is 1.09, so Neuromeka's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	-25.00%
50-Day Moving Average	26,027.00
200-Day Moving Average	25,390.15
Relative Strength Index (RSI)	53.19
Average Volume (20 Days)	34,199

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neuromeka had revenue of KRW 25.27 billion and -16.75 billion in losses. Loss per share was -1,589.00.

Revenue	25.27B
Gross Profit	4.06B
Operating Income	-19.44B
Pretax Income	-16.72B
Net Income	-16.75B
EBITDA	-17.12B
EBIT	-19.44B
Loss Per Share	-1,589.00

Full Income Statement

Balance Sheet

The company has 20.04 billion in cash and 55.59 billion in debt, giving a net cash position of -35.56 billion or -3,136.10 per share.

Cash & Cash Equivalents	20.04B
Total Debt	55.59B
Net Cash	-35.56B
Net Cash Per Share	-3,136.10
Equity (Book Value)	10.87B
Book Value Per Share	1,025.25
Working Capital	-15.86B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -21.93 billion and capital expenditures -13.69 billion, giving a free cash flow of -35.63 billion.

Operating Cash Flow	-21.93B
Capital Expenditures	-13.69B
Free Cash Flow	-35.63B
FCF Per Share	-3,142.20

Full Cash Flow Statement

Margins

Gross margin is 16.07%, with operating and profit margins of -76.93% and -66.30%.

Gross Margin	16.07%
Operating Margin	-76.93%
Pretax Margin	-66.18%
Profit Margin	-66.30%
EBITDA Margin	-67.74%
EBIT Margin	-76.93%
FCF Margin	n/a

Dividends & Yields

Neuromeka does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.18%
Shareholder Yield	-1.18%
Earnings Yield	-5.69%
FCF Yield	-12.11%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neuromeka has an Altman Z-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1
Piotroski F-Score	n/a